arrow
V

Vandana G. Abramson

Harvard Medical School
H指数:49
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Breast Cancer, Version 5.2025 Featured Updates to the NCCN Guidelines

Gradishar, W.J.; Moran, M.S.; Abraham, J.; Abranson, V.; Aft, R.; Agnese, D.; Allison, K.H.; Anderson, B.; Bailey, J.; Burstein, H.J.; et al. NCCN指南,乳腺癌,版本5。J. Natl. Compr. Cancer Netw. 2025, 23, 426–436. [Google Scholar] [CrossRef]

2025-11-013
PRE
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)

早期三阴性乳腺癌中视觉和计算评估的肿瘤浸润淋巴细胞预后价值(TBCRC-030)

2025-11-010
PRE
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
BREAST
IF7.9
2025-06-010
OAAI
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
2024-07-050
OAAI
Breast Cancer, Version 3.2024
2024-07-0120
PRE
Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer
2024-05-020
PRE
AVIATOR/ TBCRC045: A randomized phase II study of vinorelbine (N) plus trastuzumab (H) alone or combined with avelumab (A) plus /- utomilumab (U) in patients (pts) with HER2+metastatic breast cancer (MBC) (NCT03414658)
2024-05-020
PRE
HER2 heterogeneity and treatment response- associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

NCT02326974临床试验中HER2-positive乳腺癌的HER2异质性和治疗反应相关特征

2024-02-012
OAAI
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
2023-10-036
OAAI
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

TBCRC 030中三阴性乳腺癌新辅助化疗后循环肿瘤DNA与残余肿瘤负荷的关系

2023-10-0113
OAAI
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)
2023-08-313
OA
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

确定乳腺癌中的同源重组缺陷: 基因组不稳定性得分在乳腺癌亚型之间的分布不同

2023-08-175
OAAI
Breast Cancer, Version 4.2023
2023-06-01149
OA
Olaparib plus /- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
2023-04-145
PRE
Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030
2023-03-010
PRE
Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033)
2023-03-013
PRE